A novel therapy designed to treat the debilitating pain and nerve damage caused by chemotherapy has received clearance from the U.S. Food and Drug Administration to begin human trials. The candidate, SP16, aims to address chemotherapy-induced pain and peripheral neuropathy (CIPPN), a common and often long-lasting side effect for cancer patients.
The FDA's approval of the Investigational New Drug application allows Dogwood Therapeutics to proceed with clinical testing. SP16 is an intravenous therapy that works through anti-inflammatory pathways, specifically by lowering key cytokines like IL-6, IL-8, IL-1β, and TNF-alpha. Beyond calming inflammation, the drug is also designed to support tissue repair by activating signaling proteins involved in cellular growth and survival. This dual mechanism offers a non-opioid approach to a condition that currently lacks effective treatments, affecting a large portion of chemotherapy patients with symptoms like numbness, tingling, and chronic pain.
The company, collaborating with Serpin Pharma, plans to begin enrolling patients for a Phase 1b trial in mid-2026. The clinical study will be fully funded by a $2.5 million grant from the National Cancer Institute. This external funding underscores the significant unmet medical need and the potential scientific merit of the approach.
Financial Position and Pipeline
Separately, Dogwood Therapeutics recently reported its financial results. The company's net loss for the fourth quarter improved to $3.8 million, down from $8.2 million in the same period a year earlier, partly due to reduced one-time administrative costs. For the full year, research and development expenses increased, driven largely by costs associated with licensing SP16 and developing another lead candidate, Halneuron. The company ended the year with $6.5 million in cash, with additional financing expected to support operations into late 2026.
With the regulatory path now open, the focus shifts to preparing for the imminent clinical trial. If successful, SP16 could provide a much-needed therapeutic option for millions of cancer survivors who live with the persistent, painful effects of CIPPN long after their treatment has ended. The advancement represents a hopeful step toward improving quality of life during and after cancer care.